A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000855
Collaborator
(none)
35
36
1

Study Details

Study Description

Brief Summary

The purpose of this study is to examine the safety and tolerability of ZDV when given to premature infants born to HIV-positive women to prevent HIV infection.

ZDV has been used successfully to prevent the transmission of HIV from mother to child during pregnancy and birth. However, ZDV has been given to very few premature babies, and the best dose to use has not yet been determined.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

In the preliminary group of premature infants, those receiving q 6h dosing had an average trough concentration of 7.3 uM (18%). However, the premature infants in the preliminary pharmacokinetic study did not have long term follow-up to assess toxicity. Due to the potential for altered ZDV pharmacokinetics and increased toxicity in this population, an evaluation of ZDV pharmacokinetics in premature infants is proposed.

Premature infants less than or equal to 34 weeks gestational age at birth and begun on ZDV by their clinical caregivers will be entered into the protocol within the first 5 days of life. Upon entry, ZDV will be administered every 12 hours intravenously or orally. The study will require 9 serum samples for ZDV assay collected over 30 days, some additional clinical laboratory tests collected over 12 weeks, collection of 3 spot urine samples, and collection of routine clinical data.

Study Design

Study Type:
Interventional
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Safety, Tolerance, and Pharmacokinetics of Zidovudine in Premature Infants Exposed to HIV.
Actual Study Completion Date :
Feb 1, 2000

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Day to 5 Days
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Your baby may be eligible for this study if he/she:
    • Requires ZDV (as decided by your doctor) because you are HIV-positive.

    • Is 1-5 days old and was born prematurely.

    Exclusion Criteria

    Your baby will not be eligible for this study if he/she:
    • Is not expected to live 6 weeks because of severe illness.

    • Is having problems with blood pressure or is not urinating enough.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Univ of Alabama at Birmingham - Pediatric Birmingham Alabama United States 35233
    2 Phoenix Childrens Hosp Phoenix Arizona United States 85006
    3 UCSD Med Ctr / Pediatrics / Clinical Sciences La Jolla California United States 920930672
    4 Los Angeles County - USC Med Ctr Los Angeles California United States 90033
    5 UCLA Med Ctr / Pediatric Los Angeles California United States 900951752
    6 Harbor - UCLA Med Ctr / UCLA School of Medicine Los Angeles California United States 905022004
    7 Children's Hosp of Oakland Oakland California United States 946091809
    8 San Francisco Gen Hosp San Francisco California United States 94110
    9 UCSF / Moffitt Hosp - Pediatric San Francisco California United States 941430105
    10 Univ of Florida Gainesville Gainesville Florida United States 32610
    11 Univ of Florida Health Science Ctr / Pediatrics Jacksonville Florida United States 32209
    12 Univ of Miami / Jackson Memorial Hosp Miami Florida United States 33136
    13 Univ of Miami (Pediatric) Miami Florida United States 33161
    14 Emory Univ Hosp / Pediatrics Atlanta Georgia United States 30306
    15 Univ of Illinois College of Medicine / Pediatrics Chicago Illinois United States 60612
    16 Univ of Chicago Children's Hosp Chicago Illinois United States 606371470
    17 Division of Inf Diseases/ Indiana Univ Hosp Indianapolis Indiana United States 46202
    18 Children's Hosp of Boston Boston Massachusetts United States 021155724
    19 Boston City Hosp / Pediatrics Boston Massachusetts United States 02118
    20 Univ of Massachusetts Med School Worcester Massachusetts United States 016550001
    21 Univ of Mississippi Med Ctr Jackson Mississippi United States 39213
    22 Univ of Medicine & Dentistry of New Jersey / Univ Hosp Newark New Jersey United States 071032714
    23 Children's Hosp at Albany Med Ctr Albany New York United States 12208
    24 Columbia Presbyterian Med Ctr New York New York United States 10032
    25 Harlem Hosp Ctr New York New York United States 10037
    26 Univ of Rochester Med Ctr Rochester New York United States 146420001
    27 State Univ of New York at Stony Brook Stony Brook New York United States 117948111
    28 SUNY Health Sciences Ctr at Syracuse / Pediatrics Syracuse New York United States 13210
    29 Westchester Hosp Valhalla New York United States 10595
    30 Duke Univ Med Ctr Durham North Carolina United States 277103499
    31 Med Univ of South Carolina Charleston South Carolina United States 294253312
    32 Children's Med Ctr of Dallas Dallas Texas United States 75235
    33 Children's Hosp of the King's Daughters Norfolk Virginia United States 23507
    34 Med College of Virginia Richmond Virginia United States 23219
    35 Children's Hospital & Medical Center / Seattle ACTU Seattle Washington United States 981050371
    36 Univ of Puerto Rico / Univ Children's Hosp AIDS San Juan Puerto Rico 009365067

    Sponsors and Collaborators

    • National Institute of Allergy and Infectious Diseases (NIAID)

    Investigators

    • Study Chair: Mirochnick M,
    • Study Chair: Dankner D,
    • Study Chair: Capparelli E,

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    National Institute of Allergy and Infectious Diseases (NIAID)
    ClinicalTrials.gov Identifier:
    NCT00000855
    Other Study ID Numbers:
    • ACTG 331
    • 11303
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Oct 28, 2021
    Last Verified:
    Oct 1, 2021
    Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 28, 2021